PDP1 and metabolic disease: Although no specific small-molecule activators or inhibitors of PDP1 are in clinical use to date, advancing our comprehension of its regulatory roles may pave the way for the development of pharmacologically active compounds capable of modulating its activity, thereby broadening its potential as a therapeutic target for these debilitating metabolic disorders.